Safety and efficacy of a NRTI sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1 infected children.

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children

Burger, D.M.
Bastiaans, D.E.
Colbers, A.
et al.

January 2015

Contains fulltext : 152551.pdf (publisher's version ) (Open Access

Exploring the Clinical Pharmacology of Antiretroviral Agents in HIV-1 Infected Children.

Bergshoeff, A.S.

January 2004

Contains fulltext : 59063.pdf (publisher's version ) (Open Access)Current treatmen...

Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.

Verweel, G.
Burger, D.M.
Sheehan, N.L.
Bergshoeff, A.S.
Warris, A.
Knaap, L.C. van der
Driessen, G.
Groot, R. de
Hartwig, N.G.

January 2007

Contains fulltext : 52704.pdf (publisher's version ) (Closed access)BACKGROUND: Lo...

Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.

Fraaij, P.L.
Neubert, J.
Bergshoeff, A.S.
Rossum, A.M. van
Hartwig, N.G.
Schroten, H.
Korn, K.
Burger, D.M.
Groot, R. de
Niehues, T.

January 2004

Contains fulltext : 59321.pdf (publisher's version ) (Closed access)We studied a n...

Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.

Fraaij, P.L.
Neubert, J.
Bergshoeff, A.S.
Rossum, A.M. van
Hartwig, N.G.
Schroten, H.
Korn, K.
Burger, D.M.
Groot, R. de
Niehues, T.

January 2004

We studied a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen for the treatment of ...

Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.

Bergshoeff, A.S.
Fraaij, P.L.
Ndagijimana, J.
Verweel, G.
Hartwig, N.G.
Niehues, T.
Groot, R. de
Burger, D.M.

January 2005

Contains fulltext : 48066.pdf (publisher's version ) (Closed access)BACKGROUND: Nu...

Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment.

Fraaij, P.L.
Verweel, G.
Rossum, A.M. van
Hartwig, N.G.
Burger, D.M.
Groot, R. de

January 2007

Contains fulltext : 51441.pdf (publisher's version ) (Closed access)We here presen...

Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice

Gondrie, I.P.E.
Bastiaans, D.E.T.
Fraaij, P.L.
Driessen, G.J.
Knaap, L.C. van der
Visser, E.G.
Jaarsveld, P.
Groot, R. de
Hartwig, N.G.
Burger, D.M.
Rossum, A.M. van

January 2017

Contains fulltext : 176929.pdf (publisher's version ) (Closed access)BACKGROUND: T...

PRACTICE OF USING VIRAL PROTEASE INHIBITORS IN CHILDREN WITH HIV INFECTION

V.B. Denisenko
E.N. Simovan'yan
E.V. Beketova

February 2010

Selection of the most effective and safest high-active antiretroviral therapies is a critical issue ...

PRACTICE OF USING VIRAL PROTEASE INHIBITORS IN CHILDREN WITH HIV INFECTION

V.B. Denisenko
E.N. Simovan'yan
E.V. Beketova

February 2010

Selection of the most effective and safest high-active antiretroviral therapies is a critical issue ...

Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.

Ananworanich, J.
Kosalaraksa, P.
Hill, A.
Siangphoe, U.
Bergshoeff, A.S.
Pancharoen, C.
Engchanil, C.
Ruxrungtham, K.
Burger, D.M.

January 2005

Contains fulltext : 49117.pdf (publisher's version ) (Closed access)OBJECTIVE: To ...

Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.

Puthanakit, T.
Lugt, J. van der
Bunupuradah, T.
Ananworanich, J.
Gorowara, M.
Phasomsap, C.
Jupimai, T.
Boonrak, P.
Pancharoen, C.
Burger, D.M.
Ruxrungtham, K.

January 2009

Contains fulltext : 79493.pdf (publisher's version ) (Closed access)BACKGROUND: Lo...

Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

Lee (Helen Dowling Instituut), M. van der
Verweel, G.
Groot, R. de
Burger, D.M.

January 2006

Contains fulltext : 50981.pdf (publisher's version ) (Closed access)INTRODUCTION: ...

Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.

Cressey, T.R.
Green, H.
Khoo, S.
Treluyer, J.M.
Compagnucci, A.
Saidi, Y.
Lallemant, M.
Gibb, D.M.
Burger, D.M.

January 2008

Contains fulltext : 71467.pdf (publisher's version ) (Open Access)BACKGROUND: The ...

Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

Rudin, C.
Burri, M.
Shen, Y.
Rode, R.
Nadal, D.

May 2008

AIM: To evaluate the long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/rito...

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children

Burger, D.M.
Bastiaans, D.E.
Colbers, A.
et al.

January 2015

Contains fulltext : 152551.pdf (publisher's version ) (Open Access

Exploring the Clinical Pharmacology of Antiretroviral Agents in HIV-1 Infected Children.

Bergshoeff, A.S.

January 2004

Contains fulltext : 59063.pdf (publisher's version ) (Open Access)Current treatmen...

Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.

Verweel, G.
Burger, D.M.
Sheehan, N.L.
Bergshoeff, A.S.
Warris, A.
Knaap, L.C. van der
Driessen, G.
Groot, R. de
Hartwig, N.G.

January 2007

Contains fulltext : 52704.pdf (publisher's version ) (Closed access)BACKGROUND: Lo...

Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.

Fraaij, P.L.
Neubert, J.
Bergshoeff, A.S.
Rossum, A.M. van
Hartwig, N.G.
Schroten, H.
Korn, K.
Burger, D.M.
Groot, R. de
Niehues, T.

January 2004

Contains fulltext : 59321.pdf (publisher's version ) (Closed access)We studied a n...

Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.

Fraaij, P.L.
Neubert, J.
Bergshoeff, A.S.
Rossum, A.M. van
Hartwig, N.G.
Schroten, H.
Korn, K.
Burger, D.M.
Groot, R. de
Niehues, T.

January 2004

We studied a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen for the treatment of ...

Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.

Bergshoeff, A.S.
Fraaij, P.L.
Ndagijimana, J.
Verweel, G.
Hartwig, N.G.
Niehues, T.
Groot, R. de
Burger, D.M.

January 2005

Contains fulltext : 48066.pdf (publisher's version ) (Closed access)BACKGROUND: Nu...

Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment.

Fraaij, P.L.
Verweel, G.
Rossum, A.M. van
Hartwig, N.G.
Burger, D.M.
Groot, R. de

January 2007

Contains fulltext : 51441.pdf (publisher's version ) (Closed access)We here presen...

Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice

Gondrie, I.P.E.
Bastiaans, D.E.T.
Fraaij, P.L.
Driessen, G.J.
Knaap, L.C. van der
Visser, E.G.
Jaarsveld, P.
Groot, R. de
Hartwig, N.G.
Burger, D.M.
Rossum, A.M. van

January 2017

Contains fulltext : 176929.pdf (publisher's version ) (Closed access)BACKGROUND: T...

PRACTICE OF USING VIRAL PROTEASE INHIBITORS IN CHILDREN WITH HIV INFECTION

V.B. Denisenko
E.N. Simovan'yan
E.V. Beketova

February 2010

Selection of the most effective and safest high-active antiretroviral therapies is a critical issue ...

PRACTICE OF USING VIRAL PROTEASE INHIBITORS IN CHILDREN WITH HIV INFECTION

V.B. Denisenko
E.N. Simovan'yan
E.V. Beketova

February 2010

Selection of the most effective and safest high-active antiretroviral therapies is a critical issue ...

Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.

Ananworanich, J.
Kosalaraksa, P.
Hill, A.
Siangphoe, U.
Bergshoeff, A.S.
Pancharoen, C.
Engchanil, C.
Ruxrungtham, K.
Burger, D.M.

January 2005

Contains fulltext : 49117.pdf (publisher's version ) (Closed access)OBJECTIVE: To ...

Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.

Puthanakit, T.
Lugt, J. van der
Bunupuradah, T.
Ananworanich, J.
Gorowara, M.
Phasomsap, C.
Jupimai, T.
Boonrak, P.
Pancharoen, C.
Burger, D.M.
Ruxrungtham, K.

January 2009

Contains fulltext : 79493.pdf (publisher's version ) (Closed access)BACKGROUND: Lo...

Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

Lee (Helen Dowling Instituut), M. van der
Verweel, G.
Groot, R. de
Burger, D.M.

January 2006

Contains fulltext : 50981.pdf (publisher's version ) (Closed access)INTRODUCTION: ...

Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.

Cressey, T.R.
Green, H.
Khoo, S.
Treluyer, J.M.
Compagnucci, A.
Saidi, Y.
Lallemant, M.
Gibb, D.M.
Burger, D.M.

January 2008

Contains fulltext : 71467.pdf (publisher's version ) (Open Access)BACKGROUND: The ...

Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

Rudin, C.
Burri, M.
Shen, Y.
Rode, R.
Nadal, D.

May 2008

AIM: To evaluate the long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/rito...

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children

Burger, D.M.
Bastiaans, D.E.
Colbers, A.
et al.

January 2015

Contains fulltext : 152551.pdf (publisher's version ) (Open Access

Exploring the Clinical Pharmacology of Antiretroviral Agents in HIV-1 Infected Children.

Bergshoeff, A.S.

January 2004

Contains fulltext : 59063.pdf (publisher's version ) (Open Access)Current treatmen...

Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.

Verweel, G.
Burger, D.M.
Sheehan, N.L.
Bergshoeff, A.S.
Warris, A.
Knaap, L.C. van der
Driessen, G.
Groot, R. de
Hartwig, N.G.

January 2007

Contains fulltext : 52704.pdf (publisher's version ) (Closed access)BACKGROUND: Lo...

Safety and efficacy of a NRTI sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1 infected children.

Abstract

Extracted data

Safety and efficacy of a NRTI sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1 infected children.

Abstract

Extracted data

Related items

Related items